Home

J. Scott Garland

CIK 1533228 · President and CEO · last filed 2026-06-23

J. Scott Garland is a President and CEO who has filed 44 SEC Form 4 insider transactions across 10 companies since 2011. The most recent filing, for OLMA, was dated Jun 23, 2026.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

10

Total Filings

44

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
210 EAST GRAND AVE.
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OLMA Director — $10.22 — $0 4 2026-06-23
LBRX Director — $44.63 — $0 2 2026-06-05
Day One Biopharmaceuticals, Inc. (DAWN) Delisted Director — $21.53 — $0 7 2026-04-23
Enliven Therapeutics, Inc. (IMRA) Delisted Director — $14.59 — $0 2 2026-02-17
ALXO Director — $1.94 — $0 5 2026-01-21
Calithera Biosciences, Inc. (CALA) Delisted Director — $0.00 — $0 3 2022-06-03
PORTOLA PHARMACEUTICALS INC (PTLA) Delisted President and CEO 1,173 — — $0 6 2020-07-02
KPTI Director — $1.61 — $0 6 2019-06-07
Relypsa Inc (RLYP) Delisted SVP & Chief Commercial Officer 16,042 — — $0 6 2016-09-02
EXEL EVP & Chief Commerical Officer — $56.12 — $0 3 2013-09-19

Recent Filings

44 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 OLMA Grant (A) — $0 EDGAR
2026-06-05 LBRX Grant (A) — $0 EDGAR
2026-04-23 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Disp (D) — $0 EDGAR
2026-02-17 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2026-01-21 ALXO Grant (A) — $0 EDGAR
2026-01-09 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2025-11-07 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Mixed — $0 EDGAR
2025-09-12 LBRX Mixed — $0 EDGAR
2025-06-13 OLMA Grant (A) — $0 EDGAR
2025-06-04 Day One Biopharmaceuticals, Inc. (DAWN) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 44
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.